Information Provided By:
Fly News Breaks for January 27, 2020
Jan 27, 2020 | 16:13 EDT
BMO Capital analyst George Farmer initiated coverage of BioMarin Pharmaceutical with a Market Perform rating and $94 price target. The analyst says that while he believes in the potential of the company's new products, Valrox and vosoritide, developed to treat hemophilia A, "commercial uncertainties" warrant a neutral rating.
News For BMRN From the Last 2 Days
There are no results for your query BMRN